Emer­gent to shut fa­cil­i­ties and lay off work­ers as part of new CEO’s roadmap

New­ly ap­point­ed CEO Joe Pa­pa out­lined his vi­sion for Emer­gent BioSo­lu­tions, which in­cludes wind­ing down two fa­cil­i­ties and lay­ing off 300 em­ploy­ees to save $80 mil­lion.

Ac­cord­ing to an Al­phaSense tran­script on Wednes­day’s first-quar­ter earn­ings call, Pa­pa said that go­ing for­ward, the com­pa­ny will fo­cus on its core prod­ucts such as grow­ing its over-the-counter opi­oid over­dose nasal spray Nar­can and its med­ical coun­ter­mea­sures busi­ness. Ad­di­tion­al­ly, a new chief sci­en­tif­ic of­fi­cer po­si­tion will be cre­at­ed to im­prove Emer­gent’s long-term prod­uct pipeline, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER